Clinical Trials Browser

NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Clinical Trials

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

INTUITT-NF2

Assessment of Patient Experience With Auto-Captioning Glasses in NF2-Related-Schwannomatosis

NF110

Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II

Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing

Study of Aspirin in Patients With Vestibular Schwannoma

Doxycycline in Cutaneous Schwannoma (NF2)

Exploratory Evaluation of AR-42 Histone Deacetylase Inhibitor in the Treatment of Vestibular Schwannoma and Meningioma

POPLAR-NF2

SEL-TH-1601

Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Vestibular Precision: Physiology & Pathophysiology

MERLIN

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Icotinib

A Single Center Pilot Study to Assess the Intra-observer Reliability of Measuring Muscle Strength Using a Hand Held Dynamometer in Children and Adults With Neurofibromatosis Type 1 (NF1) and Type 2 (NF2)

Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas

Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Concentration and Activity of Lapatinib in Vestibular Schwannomas

Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas

Effect of Implant Position on Magnetic Resonance Image Distortion

PTC299 for Treatment of Neurofibromatosis Type 2

Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2)

Resiliency Training for Patients With NF2 Via Videoconferencing With Skype

Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2

AFINF2

Endostatin

Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype

Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2

An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors